Aveo Pharmaceuticals Inc AVEO:NASDAQ

Last Price$6.71Cboe Real-Time Last Sale as of 10:55AM ET 6/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.13(1.98%)
Bid (Size)$6.72 (2)
Ask (Size)$6.73 (5)
Day Low / High$6.41 - 6.80
Volume155.4 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/27/2022


Aveo Pharmaceuticals Inc ( NASDAQ )

Price: $6.71
Change: +0.13 (1.98%)
Volume: 155.4 K
10:55AM ET 6/27/2022

Evelo Biosciences Inc ( NASDAQ )

Price: $2.12
Change: +0.05 (2.42%)
Volume: 65.5 K
10:49AM ET 6/27/2022

Viking Therapeutics Inc ( NASDAQ )

Price: $2.85
Change: -0.03 (1.04%)
Volume: 293.4 K
10:59AM ET 6/27/2022

Xeris Biopharma Holdings Inc ( NASDAQ )

Price: $1.67
Change: +0.04 (2.15%)
Volume: 399.5 K
11:00AM ET 6/27/2022

G1 Therapeutics Inc ( NASDAQ )

Price: $5.37
Change: -0.17 (3.07%)
Volume: 169.2 K
11:00AM ET 6/27/2022

Read more news Recent News

AVEO Pharmaceuticals, Eli Lilly Partner in Clinical Trial to Assess Potential Treatment in Patients With Head, Neck Cancer
9:30AM ET 6/22/2022 MT Newswires

AVEO Pharmaceuticals (AVEO) said it secured a clinical trial partnership and supply agreement in North America with Eli Lilly and Co. (LLY) to assess...

-- Earnings Flash (AVEO) AVEO PHARMACEUTICALS Reports Q1 Revenue $20.9M, vs. Street Est of $20.8M
7:01AM ET 5/05/2022 MT Newswires


--JonesTrading Initiates AVEO Pharmaceuticals With Buy Rating, $12 Price Target
2:25PM ET 3/14/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AVEO Pharmaceuticals Net Loss Narrows, Revenue Increases in Q4
7:28AM ET 3/14/2022 MT Newswires

AVEO Pharmaceuticals (AVEO) reported a Q4 net loss Monday of $0.21 per share, compared with a loss of $0.44 a year earlier. Analysts polled by Capital IQ...

Company Profile

Business DescriptionAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. View company web site for more details
Address30 Winter Street
Boston, Massachusetts 02108
Number of Employees17
Recent SEC Filing06/08/20224
President, Chief Executive Officer & DirectorMichael P. Bailey
Chief Operating OfficerJebediah Ledell
Chief Financial OfficerErick J. Lucera
Vice President-Information TechnologyMatthew Coulter

Company Highlights

Price Open$6.50
Previous Close$6.58
52 Week Range$3.06 - 7.55
Market Capitalization$231.3 M
Shares Outstanding34.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.26
Beta vs. S&P 500N/A
Revenue$5.4 M
Net Profit Margin-67.57%
Return on Equity-85.29%

Analyst Ratings as of 03/14/2022

Consensus RecommendationConsensus Icon
Powered by Factset